LLY vs STTK
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. STTK: A clinical-stage biotech developing potentially first-in-class DR3-blocking antibodies to improve treatment outcomes for inflammatory and immune-mediated diseases like Crohn's.
Side-by-side fundamentals
| Metric | LLY | STTK | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $1,270.75 | $5.58 | |
| Market cap | $1.20T | $560M | |
| P/E as of 2026-10-21 | 42.66 | n/a | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | 0.87 | n/a | |
| Net margin FY2025, SEC XBRL | +31.7% | -4880.9% | LLY higher |
| Operating margin FY2025, SEC XBRL | n/a | -5150.8% | |
| ROE FY2025, SEC XBRL | +77.8% | -59.2% | LLY higher |
| ROA FY2025, SEC XBRL | +18.4% | -53.6% | LLY higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.62 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +44.7% | -82.5% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +15.3% | LLY higher |
| Dividend yield as of 2026-09-03 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 10 | 0 | LLY higher |
| Beta as of 2026-09-03 | 0.54 | 1.31 | |
| 1-year return as of 2026-10-21 close | +58.9% | +190.6% | STTK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.